# Beyond exercise and appetite: The expanding biology and therapeutic potential of N-lactoyl-phenylalanine

**Authors:** Olaiya Peter Oni, Barry Scott, Lily C. Schwartz, Tyson J. MacCormack, Mohammed Hankir, Jillian L. Rourke

PMC · DOI: 10.1016/j.jpet.2025.103798 · 2025-12-18

## TL;DR

N-lactoyl-phenylalanine (Lac-Phe) is a metabolite that connects metabolism to appetite control and inflammation, showing potential as a therapeutic target for obesity and related conditions.

## Contribution

This review highlights Lac-Phe's expanding biological roles and therapeutic potential beyond exercise and appetite regulation.

## Key findings

- Lac-Phe suppresses appetite and reduces body weight in preclinical models of obesity.
- Lac-Phe promotes anti-inflammatory effects in models of colitis and spinal cord injury.
- Circulating Lac-Phe levels rise in conditions like mitochondrial dysfunction and sepsis.

## Abstract

N-lactoyl-phenylalanine (Lac-Phe) has emerged as a signaling metabolite connecting cellular metabolism to systemic physiology. Synthesized through carnosine dipeptidase 2-mediated conjugation of lactate and phenylalanine, Lac-Phe increases acutely in response to exercise and feeding, the primary drivers of its elevation under physiologic conditions. In preclinical models, Lac-Phe acts as a potent regulator of energy balance. Its administration suppresses appetite and reduces body weight in obesity, whereas pharmacologic interventions such as metformin elevate circulating Lac-Phe to produce similar anorexigenic effects. Converging evidence implicates central mechanisms, including inhibition of orexigenic agouti-related peptide neurons, positioning Lac-Phe as a mediator linking peripheral metabolic signals to appetite control. The first human Lac-Phe clinical trial in individuals with obesity began dosing in 2025, evaluating appetite suppression and glucose-lowering effects. Beyond metabolism, Lac-Phe promotes anti-inflammatory macrophage polarization, conferring protection in murine models of colitis and spinal cord injury. Circulating Lac-Phe also rises in conditions such as mitochondrial dysfunction, sepsis, and phenylketonuria, suggesting broader associations with perturbed energy metabolism and systemic stress responses. This review integrates current knowledge spanning molecular mechanisms, physiological regulation, and clinical translation. We examine Lac-Phe biosynthesis, tissue distribution, and regulatory patterns across physiological and disease states, and highlight emerging mechanisms of action in metabolic and inflammatory signaling. Finally, we discuss key knowledge gaps, highlighting the need to define targets, transporters, and tissue sources to shape the next phase of discovery. Collectively, these advances position Lac-Phe at the forefront of exerkine biology and as a promising molecular link between metabolism, immunity, and therapeutic innovation.

Evidence across molecular, physiological, and translational domains positions Lac-Phe as a promising therapeutic target. This review frames our understanding of Lac-Phe biology—from its biosynthesis to its roles in energy balance and outlines the key questions that will define ongoing discovery.

## Linked entities

- **Chemicals:** N-lactoyl-phenylalanine (PubChem CID 11075454), lactate (PubChem CID 61503), phenylalanine (PubChem CID 994), metformin (PubChem CID 4091)
- **Diseases:** obesity (MONDO:0011122), colitis (MONDO:0005292), spinal cord injury (MONDO:0043797), phenylketonuria (MONDO:0009861)

## Full-text entities

- **Diseases:** sepsis (MESH:D018805), colitis (MESH:D003092), mitochondrial dysfunction (MESH:D028361), obesity (MESH:D009765), inflammatory (MESH:D007249), phenylketonuria (MESH:D010661), spinal cord injury (MESH:D013119)
- **Chemicals:** lactate (MESH:D019344), metformin (MESH:D008687), glucose (MESH:D005947), phenylalanine (MESH:D010649), Lac-Phe (MESH:C000723769)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12975387/full.md

---
Source: https://tomesphere.com/paper/PMC12975387